1 Market Overview

1 Market Overview

1.1 Product Overview and Scope of PD-1 and PD-L1 Antibody

1.2 Classification of PD-1 and PD-L1 Antibody by Type

1.2.1 Overview: Global PD-1 and PD-L1 Antibody Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global PD-1 and PD-L1 Antibody Revenue Market Share by Type in 2021

1.2.3 PD-1 inhibitor

1.2.4 PD-L1 inhibitor

1.3 Global PD-1 and PD-L1 Antibody Market by Application

1.3.1 Overview: Global PD-1 and PD-L1 Antibody Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Solid Tumors

1.3.3 Blood-related Tumors

1.4 Global PD-1 and PD-L1 Antibody Market Size & Forecast

1.5 Global PD-1 and PD-L1 Antibody Market Size and Forecast by Region

1.5.1 Global PD-1 and PD-L1 Antibody Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global PD-1 and PD-L1 Antibody Market Size by Region, (2017-2022)

1.5.3 North America PD-1 and PD-L1 Antibody Market Size and Prospect (2017-2028)

1.5.4 Europe PD-1 and PD-L1 Antibody Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific PD-1 and PD-L1 Antibody Market Size and Prospect (2017-2028)

1.5.6 South America PD-1 and PD-L1 Antibody Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa PD-1 and PD-L1 Antibody Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 PD-1 and PD-L1 Antibody Market Drivers

1.6.2 PD-1 and PD-L1 Antibody Market Restraints

1.6.3 PD-1 and PD-L1 Antibody Trends Analysis

2 Company Profiles

2 Company Profiles

2.1 AstraZeneca

2.1.1 AstraZeneca Details

2.1.2 AstraZeneca Major Business

2.1.3 AstraZeneca PD-1 and PD-L1 Antibody Product and Solutions

2.1.4 AstraZeneca PD-1 and PD-L1 Antibody Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 AstraZeneca Recent Developments and Future Plans

2.2 Bristol-Myers Squibb

2.2.1 Bristol-Myers Squibb Details

2.2.2 Bristol-Myers Squibb Major Business

2.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Antibody Product and Solutions

2.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Antibody Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Bristol-Myers Squibb Recent Developments and Future Plans

2.3 F. Hoffmann-La Roche

2.3.1 F. Hoffmann-La Roche Details

2.3.2 F. Hoffmann-La Roche Major Business

2.3.3 F. Hoffmann-La Roche PD-1 and PD-L1 Antibody Product and Solutions

2.3.4 F. Hoffmann-La Roche PD-1 and PD-L1 Antibody Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 F. Hoffmann-La Roche Recent Developments and Future Plans

2.4 Merck

2.4.1 Merck Details

2.4.2 Merck Major Business

2.4.3 Merck PD-1 and PD-L1 Antibody Product and Solutions

2.4.4 Merck PD-1 and PD-L1 Antibody Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Merck Recent Developments and Future Plans

2.5 Pfizer

2.5.1 Pfizer Details

2.5.2 Pfizer Major Business

2.5.3 Pfizer PD-1 and PD-L1 Antibody Product and Solutions

2.5.4 Pfizer PD-1 and PD-L1 Antibody Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Pfizer Recent Developments and Future Plans

2.6 Roche

2.6.1 Roche Details

2.6.2 Roche Major Business

2.6.3 Roche PD-1 and PD-L1 Antibody Product and Solutions

2.6.4 Roche PD-1 and PD-L1 Antibody Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Roche Recent Developments and Future Plans

2.7 Novartis

2.7.1 Novartis Details

2.7.2 Novartis Major Business

2.7.3 Novartis PD-1 and PD-L1 Antibody Product and Solutions

2.7.4 Novartis PD-1 and PD-L1 Antibody Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Novartis Recent Developments and Future Plans

2.8 Jiangsu HengRui Medicine

2.8.1 Jiangsu HengRui Medicine Details

2.8.2 Jiangsu HengRui Medicine Major Business

2.8.3 Jiangsu HengRui Medicine PD-1 and PD-L1 Antibody Product and Solutions

2.8.4 Jiangsu HengRui Medicine PD-1 and PD-L1 Antibody Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Jiangsu HengRui Medicine Recent Developments and Future Plans

2.9 Innovent

2.9.1 Innovent Details

2.9.2 Innovent Major Business

2.9.3 Innovent PD-1 and PD-L1 Antibody Product and Solutions

2.9.4 Innovent PD-1 and PD-L1 Antibody Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Innovent Recent Developments and Future Plans

2.10 Eli Lilly

2.10.1 Eli Lilly Details

2.10.2 Eli Lilly Major Business

2.10.3 Eli Lilly PD-1 and PD-L1 Antibody Product and Solutions

2.10.4 Eli Lilly PD-1 and PD-L1 Antibody Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Eli Lilly Recent Developments and Future Plans

2.11 GlaxoSmithKline

2.11.1 GlaxoSmithKline Details

2.11.2 GlaxoSmithKline Major Business

2.11.3 GlaxoSmithKline PD-1 and PD-L1 Antibody Product and Solutions

2.11.4 GlaxoSmithKline PD-1 and PD-L1 Antibody Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 GlaxoSmithKline Recent Developments and Future Plans

3 Market Competition, by Players

3 Market Competition, by Players

3.1 Global PD-1 and PD-L1 Antibody Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 PD-1 and PD-L1 Antibody Players Market Share in 2021

3.2.2 Top 10 PD-1 and PD-L1 Antibody Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 PD-1 and PD-L1 Antibody Players Head Office, Products and Services Provided

3.4 PD-1 and PD-L1 Antibody Mergers & Acquisitions

3.5 PD-1 and PD-L1 Antibody New Entrants and Expansion Plans

4 Market Size Segment by Type

4 Market Size Segment by Type

4.1 Global PD-1 and PD-L1 Antibody Revenue and Market Share by Type (2017-2022)

4.2 Global PD-1 and PD-L1 Antibody Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5 Market Size Segment by Application

5.1 Global PD-1 and PD-L1 Antibody Revenue Market Share by Application (2017-2022)

5.2 Global PD-1 and PD-L1 Antibody Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6 North America by Country, by Type, and by Application

6.1 North America PD-1 and PD-L1 Antibody Revenue by Type (2017-2028)

6.2 North America PD-1 and PD-L1 Antibody Revenue by Application (2017-2028)

6.3 North America PD-1 and PD-L1 Antibody Market Size by Country

6.3.1 North America PD-1 and PD-L1 Antibody Revenue by Country (2017-2028)

6.3.2 United States PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

6.3.3 Canada PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

6.3.4 Mexico PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7 Europe by Country, by Type, and by Application

7.1 Europe PD-1 and PD-L1 Antibody Revenue by Type (2017-2028)

7.2 Europe PD-1 and PD-L1 Antibody Revenue by Application (2017-2028)

7.3 Europe PD-1 and PD-L1 Antibody Market Size by Country

7.3.1 Europe PD-1 and PD-L1 Antibody Revenue by Country (2017-2028)

7.3.2 Germany PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

7.3.3 France PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

7.3.4 United Kingdom PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

7.3.5 Russia PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

7.3.6 Italy PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific PD-1 and PD-L1 Antibody Revenue by Type (2017-2028)

8.2 Asia-Pacific PD-1 and PD-L1 Antibody Revenue by Application (2017-2028)

8.3 Asia-Pacific PD-1 and PD-L1 Antibody Market Size by Region

8.3.1 Asia-Pacific PD-1 and PD-L1 Antibody Revenue by Region (2017-2028)

8.3.2 China PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

8.3.3 Japan PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

8.3.4 South Korea PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

8.3.5 India PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

8.3.7 Australia PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9 South America by Country, by Type, and by Application

9.1 South America PD-1 and PD-L1 Antibody Revenue by Type (2017-2028)

9.2 South America PD-1 and PD-L1 Antibody Revenue by Application (2017-2028)

9.3 South America PD-1 and PD-L1 Antibody Market Size by Country

9.3.1 South America PD-1 and PD-L1 Antibody Revenue by Country (2017-2028)

9.3.2 Brazil PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

9.3.3 Argentina PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa PD-1 and PD-L1 Antibody Revenue by Type (2017-2028)

10.2 Middle East & Africa PD-1 and PD-L1 Antibody Revenue by Application (2017-2028)

10.3 Middle East & Africa PD-1 and PD-L1 Antibody Market Size by Country

10.3.1 Middle East & Africa PD-1 and PD-L1 Antibody Revenue by Country (2017-2028)

10.3.2 Turkey PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

10.3.4 UAE PD-1 and PD-L1 Antibody Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

11 Research Findings and Conclusion

12 Appendix

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global PD-1 and PD-L1 Antibody Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global PD-1 and PD-L1 Antibody Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market PD-1 and PD-L1 Antibody Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global PD-1 and PD-L1 Antibody Revenue (USD Million) by Region (2017-2022)

Table 5. Global PD-1 and PD-L1 Antibody Revenue Market Share by Region (2023-2028)

Table 6. AstraZeneca Corporate Information, Head Office, and Major Competitors

Table 7. AstraZeneca Major Business

Table 8. AstraZeneca PD-1 and PD-L1 Antibody Product and Solutions

Table 9. AstraZeneca PD-1 and PD-L1 Antibody Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors

Table 11. Bristol-Myers Squibb Major Business

Table 12. Bristol-Myers Squibb PD-1 and PD-L1 Antibody Product and Solutions

Table 13. Bristol-Myers Squibb PD-1 and PD-L1 Antibody Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. F. Hoffmann-La Roche Corporate Information, Head Office, and Major Competitors

Table 15. F. Hoffmann-La Roche Major Business

Table 16. F. Hoffmann-La Roche PD-1 and PD-L1 Antibody Product and Solutions

Table 17. F. Hoffmann-La Roche PD-1 and PD-L1 Antibody Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Merck Corporate Information, Head Office, and Major Competitors

Table 19. Merck Major Business

Table 20. Merck PD-1 and PD-L1 Antibody Product and Solutions

Table 21. Merck PD-1 and PD-L1 Antibody Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Pfizer Corporate Information, Head Office, and Major Competitors

Table 23. Pfizer Major Business

Table 24. Pfizer PD-1 and PD-L1 Antibody Product and Solutions

Table 25. Pfizer PD-1 and PD-L1 Antibody Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Roche Corporate Information, Head Office, and Major Competitors

Table 27. Roche Major Business

Table 28. Roche PD-1 and PD-L1 Antibody Product and Solutions

Table 29. Roche PD-1 and PD-L1 Antibody Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Novartis Corporate Information, Head Office, and Major Competitors

Table 31. Novartis Major Business

Table 32. Novartis PD-1 and PD-L1 Antibody Product and Solutions

Table 33. Novartis PD-1 and PD-L1 Antibody Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Jiangsu HengRui Medicine Corporate Information, Head Office, and Major Competitors

Table 35. Jiangsu HengRui Medicine Major Business

Table 36. Jiangsu HengRui Medicine PD-1 and PD-L1 Antibody Product and Solutions

Table 37. Jiangsu HengRui Medicine PD-1 and PD-L1 Antibody Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Innovent Corporate Information, Head Office, and Major Competitors

Table 39. Innovent Major Business

Table 40. Innovent PD-1 and PD-L1 Antibody Product and Solutions

Table 41. Innovent PD-1 and PD-L1 Antibody Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Eli Lilly Corporate Information, Head Office, and Major Competitors

Table 43. Eli Lilly Major Business

Table 44. Eli Lilly PD-1 and PD-L1 Antibody Product and Solutions

Table 45. Eli Lilly PD-1 and PD-L1 Antibody Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors

Table 47. GlaxoSmithKline Major Business

Table 48. GlaxoSmithKline PD-1 and PD-L1 Antibody Product and Solutions

Table 49. GlaxoSmithKline PD-1 and PD-L1 Antibody Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Global PD-1 and PD-L1 Antibody Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 51. Global PD-1 and PD-L1 Antibody Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 52. Breakdown of PD-1 and PD-L1 Antibody by Company Type (Tier 1, Tier 2 and Tier 3)

Table 53. PD-1 and PD-L1 Antibody Players Head Office, Products and Services Provided

Table 54. PD-1 and PD-L1 Antibody Mergers & Acquisitions in the Past Five Years

Table 55. PD-1 and PD-L1 Antibody New Entrants and Expansion Plans

Table 56. Global PD-1 and PD-L1 Antibody Revenue (USD Million) by Type (2017-2022)

Table 57. Global PD-1 and PD-L1 Antibody Revenue Share by Type (2017-2022)

Table 58. Global PD-1 and PD-L1 Antibody Revenue Forecast by Type (2023-2028)

Table 59. Global PD-1 and PD-L1 Antibody Revenue by Application (2017-2022)

Table 60. Global PD-1 and PD-L1 Antibody Revenue Forecast by Application (2023-2028)

Table 61. North America PD-1 and PD-L1 Antibody Revenue by Type (2017-2022) & (USD Million)

Table 62. North America PD-1 and PD-L1 Antibody Revenue by Type (2023-2028) & (USD Million)

Table 63. North America PD-1 and PD-L1 Antibody Revenue by Application (2017-2022) & (USD Million)

Table 64. North America PD-1 and PD-L1 Antibody Revenue by Application (2023-2028) & (USD Million)

Table 65. North America PD-1 and PD-L1 Antibody Revenue by Country (2017-2022) & (USD Million)

Table 66. North America PD-1 and PD-L1 Antibody Revenue by Country (2023-2028) & (USD Million)

Table 67. Europe PD-1 and PD-L1 Antibody Revenue by Type (2017-2022) & (USD Million)

Table 68. Europe PD-1 and PD-L1 Antibody Revenue by Type (2023-2028) & (USD Million)

Table 69. Europe PD-1 and PD-L1 Antibody Revenue by Application (2017-2022) & (USD Million)

Table 70. Europe PD-1 and PD-L1 Antibody Revenue by Application (2023-2028) & (USD Million)

Table 71. Europe PD-1 and PD-L1 Antibody Revenue by Country (2017-2022) & (USD Million)

Table 72. Europe PD-1 and PD-L1 Antibody Revenue by Country (2023-2028) & (USD Million)

Table 73. Asia-Pacific PD-1 and PD-L1 Antibody Revenue by Type (2017-2022) & (USD Million)

Table 74. Asia-Pacific PD-1 and PD-L1 Antibody Revenue by Type (2023-2028) & (USD Million)

Table 75. Asia-Pacific PD-1 and PD-L1 Antibody Revenue by Application (2017-2022) & (USD Million)

Table 76. Asia-Pacific PD-1 and PD-L1 Antibody Revenue by Application (2023-2028) & (USD Million)

Table 77. Asia-Pacific PD-1 and PD-L1 Antibody Revenue by Region (2017-2022) & (USD Million)

Table 78. Asia-Pacific PD-1 and PD-L1 Antibody Revenue by Region (2023-2028) & (USD Million)

Table 79. South America PD-1 and PD-L1 Antibody Revenue by Type (2017-2022) & (USD Million)

Table 80. South America PD-1 and PD-L1 Antibody Revenue by Type (2023-2028) & (USD Million)

Table 81. South America PD-1 and PD-L1 Antibody Revenue by Application (2017-2022) & (USD Million)

Table 82. South America PD-1 and PD-L1 Antibody Revenue by Application (2023-2028) & (USD Million)

Table 83. South America PD-1 and PD-L1 Antibody Revenue by Country (2017-2022) & (USD Million)

Table 84. South America PD-1 and PD-L1 Antibody Revenue by Country (2023-2028) & (USD Million)

Table 85. Middle East & Africa PD-1 and PD-L1 Antibody Revenue by Type (2017-2022) & (USD Million)

Table 86. Middle East & Africa PD-1 and PD-L1 Antibody Revenue by Type (2023-2028) & (USD Million)

Table 87. Middle East & Africa PD-1 and PD-L1 Antibody Revenue by Application (2017-2022) & (USD Million)

Table 88. Middle East & Africa PD-1 and PD-L1 Antibody Revenue by Application (2023-2028) & (USD Million)

Table 89. Middle East & Africa PD-1 and PD-L1 Antibody Revenue by Country (2017-2022) & (USD Million)

Table 90. Middle East & Africa PD-1 and PD-L1 Antibody Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. PD-1 and PD-L1 Antibody Picture

Figure 2. Global PD-1 and PD-L1 Antibody Revenue Market Share by Type in 2021

Figure 3. PD-1 inhibitor

Figure 4. PD-L1 inhibitor

Figure 5. PD-1 and PD-L1 Antibody Revenue Market Share by Application in 2021

Figure 6. Solid Tumors Picture

Figure 7. Blood-related Tumors Picture

Figure 8. Global PD-1 and PD-L1 Antibody Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 9. Global PD-1 and PD-L1 Antibody Revenue and Forecast (2017-2028) & (USD Million)

Figure 10. Global PD-1 and PD-L1 Antibody Revenue Market Share by Region (2017-2028)

Figure 11. Global PD-1 and PD-L1 Antibody Revenue Market Share by Region in 2021

Figure 12. North America PD-1 and PD-L1 Antibody Revenue (USD Million) and Growth Rate (2017-2028)

Figure 13. Europe PD-1 and PD-L1 Antibody Revenue (USD Million) and Growth Rate (2017-2028)

Figure 14. Asia-Pacific PD-1 and PD-L1 Antibody Revenue (USD Million) and Growth Rate (2017-2028)

Figure 15. South America PD-1 and PD-L1 Antibody Revenue (USD Million) and Growth Rate (2017-2028)

Figure 16. Middle East and Africa PD-1 and PD-L1 Antibody Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. PD-1 and PD-L1 Antibody Market Drivers

Figure 18. PD-1 and PD-L1 Antibody Market Restraints

Figure 19. PD-1 and PD-L1 Antibody Market Trends

Figure 20. AstraZeneca Recent Developments and Future Plans

Figure 21. Bristol-Myers Squibb Recent Developments and Future Plans

Figure 22. F. Hoffmann-La Roche Recent Developments and Future Plans

Figure 23. Merck Recent Developments and Future Plans

Figure 24. Pfizer Recent Developments and Future Plans

Figure 25. Roche Recent Developments and Future Plans

Figure 26. Novartis Recent Developments and Future Plans

Figure 27. Jiangsu HengRui Medicine Recent Developments and Future Plans

Figure 28. Innovent Recent Developments and Future Plans

Figure 29. Eli Lilly Recent Developments and Future Plans

Figure 30. GlaxoSmithKline Recent Developments and Future Plans

Figure 31. Global PD-1 and PD-L1 Antibody Revenue Share by Players in 2021

Figure 32. PD-1 and PD-L1 Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 33. Global Top 3 Players PD-1 and PD-L1 Antibody Revenue Market Share in 2021

Figure 34. Global Top 10 Players PD-1 and PD-L1 Antibody Revenue Market Share in 2021

Figure 35. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 36. Global PD-1 and PD-L1 Antibody Revenue Share by Type in 2021

Figure 37. Global PD-1 and PD-L1 Antibody Market Share Forecast by Type (2023-2028)

Figure 38. Global PD-1 and PD-L1 Antibody Revenue Share by Application in 2021

Figure 39. Global PD-1 and PD-L1 Antibody Market Share Forecast by Application (2023-2028)

Figure 40. North America PD-1 and PD-L1 Antibody Sales Market Share by Type (2017-2028)

Figure 41. North America PD-1 and PD-L1 Antibody Sales Market Share by Application (2017-2028)

Figure 42. North America PD-1 and PD-L1 Antibody Revenue Market Share by Country (2017-2028)

Figure 43. United States PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 44. Canada PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 45. Mexico PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 46. Europe PD-1 and PD-L1 Antibody Sales Market Share by Type (2017-2028)

Figure 47. Europe PD-1 and PD-L1 Antibody Sales Market Share by Application (2017-2028)

Figure 48. Europe PD-1 and PD-L1 Antibody Revenue Market Share by Country (2017-2028)

Figure 49. Germany PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 50. France PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 51. United Kingdom PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. Russia PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. Italy PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. Asia-Pacific PD-1 and PD-L1 Antibody Sales Market Share by Type (2017-2028)

Figure 55. Asia-Pacific PD-1 and PD-L1 Antibody Sales Market Share by Application (2017-2028)

Figure 56. Asia-Pacific PD-1 and PD-L1 Antibody Revenue Market Share by Region (2017-2028)

Figure 57. China PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. Japan PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. South Korea PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. India PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. Southeast Asia PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. Australia PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. South America PD-1 and PD-L1 Antibody Sales Market Share by Type (2017-2028)

Figure 64. South America PD-1 and PD-L1 Antibody Sales Market Share by Application (2017-2028)

Figure 65. South America PD-1 and PD-L1 Antibody Revenue Market Share by Country (2017-2028)

Figure 66. Brazil PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. Argentina PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Middle East and Africa PD-1 and PD-L1 Antibody Sales Market Share by Type (2017-2028)

Figure 69. Middle East and Africa PD-1 and PD-L1 Antibody Sales Market Share by Application (2017-2028)

Figure 70. Middle East and Africa PD-1 and PD-L1 Antibody Revenue Market Share by Country (2017-2028)

Figure 71. Turkey PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 72. Saudi Arabia PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 73. UAE PD-1 and PD-L1 Antibody Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. Methodology

Figure 75. Research Process and Data Source